BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28934369)

  • 1. In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.
    Marsden MD; Loy BA; Wu X; Ramirez CM; Schrier AJ; Murray D; Shimizu A; Ryckbosch SM; Near KE; Chun TW; Wender PA; Zack JA
    PLoS Pathog; 2017 Sep; 13(9):e1006575. PubMed ID: 28934369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.
    Marsden MD; Wu X; Navab SM; Loy BA; Schrier AJ; DeChristopher BA; Shimizu AJ; Hardman CT; Ho S; Ramirez CM; Wender PA; Zack JA
    Virology; 2018 Jul; 520():83-93. PubMed ID: 29800728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
    Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
    J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
    Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
    PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of latent HIV using drug-loaded nanoparticles.
    Kovochich M; Marsden MD; Zack JA
    PLoS One; 2011 Apr; 6(4):e18270. PubMed ID: 21483687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency.
    Pérez M; de Vinuesa AG; Sanchez-Duffhues G; Marquez N; Bellido ML; Muñoz-Fernandez MA; Moreno S; Castor TP; Calzado MA; Muñoz E
    Curr HIV Res; 2010 Sep; 8(6):418-29. PubMed ID: 20636281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
    De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
    Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secreted factors induced by PKC modulators do not indirectly cause HIV latency reversal.
    Moran JA; Ranjan A; Hourani R; Kim JT; Wender PA; Zack JA; Marsden MD
    Virology; 2023 Apr; 581():8-14. PubMed ID: 36842270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV.
    Wender PA; Hardman CT; Ho S; Jeffreys MS; Maclaren JK; Quiroz RV; Ryckbosch SM; Shimizu AJ; Sloane JL; Stevens MC
    Science; 2017 Oct; 358(6360):218-223. PubMed ID: 29026042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro.
    DeChristopher BA; Loy BA; Marsden MD; Schrier AJ; Zack JA; Wender PA
    Nat Chem; 2012 Sep; 4(9):705-10. PubMed ID: 22914190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window.
    Sloane JL; Benner NL; Keenan KN; Zang X; Soliman MSA; Wu X; Dimapasoc M; Chun TW; Marsden MD; Zack JA; Wender PA
    Proc Natl Acad Sci U S A; 2020 May; 117(20):10688-10698. PubMed ID: 32371485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response.
    Peng W; Hong Z; Chen X; Gao H; Dai Z; Zhao J; Liu W; Li D; Deng K
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo.
    Beans EJ; Fournogerakis D; Gauntlett C; Heumann LV; Kramer R; Marsden MD; Murray D; Chun TW; Zack JA; Wender PA
    Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11698-703. PubMed ID: 23812750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
    Bullen CK; Laird GM; Durand CM; Siliciano JD; Siliciano RF
    Nat Med; 2014 Apr; 20(4):425-9. PubMed ID: 24658076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4
    Zerbato JM; Tachedjian G; Sluis-Cremer N
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Novel PKC Activator 10-Methyl-Aplog-1 Combined with JQ1 Induced Strong and Synergistic HIV Reactivation with Tolerable Global T Cell Activation.
    Washizaki A; Murata M; Seki Y; Kikumori M; Tang Y; Tan W; Wardani NP; Irie K; Akari H
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
    Kim Y; Anderson JL; Lewin SR
    Cell Host Microbe; 2018 Jan; 23(1):14-26. PubMed ID: 29324227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.